- Home
- CXAI vs CRIS Comparison
CXAI vs CRIS Comparison
Compare CXAI & CRIS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | CXAI | CRIS |
|---|---|---|
| Founded | N/A | 2000 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | EDP Services | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 8.9M | 14.0M |
| IPO Year | N/A | 2000 |
Fundamental Metrics
Financial Performance| Metric | CXAI | CRIS |
|---|---|---|
| Price | $0.26 | $0.76 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $16.67 |
| AVG Volume (30 Days) | ★ 10.6M | 123.5K |
| Earning Date | 03-20-2026 | 03-19-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 23.21 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $9,898,000.00 |
| Revenue This Year | N/A | $32.24 |
| Revenue Next Year | $70.21 | $66.94 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 31.50 |
| 52 Week Low | $0.16 | $0.75 |
| 52 Week High | $1.49 | $3.13 |
Technical Indicators
Market Signals| Indicator | CXAI | CRIS |
|---|---|---|
| Relative Strength Index (RSI) | 55.15 | 29.42 |
| Support Level | $0.24 | N/A |
| Resistance Level | $0.32 | $1.04 |
| Average True Range (ATR) | 0.04 | 0.07 |
| MACD | 0.01 | -0.03 |
| Stochastic Oscillator | 60.31 | 3.28 |
Price Performance
Historical ComparisonAbout CXAI CXApp Inc.
CXApp Inc is a provider of AI-powered employee experience solutions, delivering enterprise-grade software that enhances workplace engagement, productivity, and operational efficiency. The company's flagship product, the CXAI Platform, provides a comprehensive suite of tools designed to empower employees and enable organizations to create smarter workplaces. The product's key components include CXAI Apps, CXAI BTS, and CXAI-VU. The company generates the majority of its revenue from Licenses.
About CRIS Curis Inc.
Curis Inc is a biotechnology company that develops and commercializes drugs and therapies in the immuno-oncology and precision oncology therapeutic areas. The company targets solid tumors, diffuse large B-cell lymphoma, solid tumors or lymphomas, hematological cancers, and others. Its pipeline products include Fimepinostat, CA-170, CA-4948, CA-327, and Erivedge.